Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation (DEAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02937168
Recruitment Status : Terminated (The study was terminated early due to challenges in recruitment. The decision to terminate the study was not related to any safety issues or concerns.)
First Posted : October 18, 2016
Results First Posted : August 6, 2019
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )

Brief Summary:
This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic phenotype and 2) to examine the utility of PET/CT for demonstrating that reslizumab produces a reduction in lung inflammation in participants with severe asthma and an eosinophilic phenotype .

Condition or disease Intervention/treatment Phase
Asthma Drug: Reslizumab Drug: Fludeoxyglucose F 18 (FDG) Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Distribution of Eosinophils in Asthma After Reslizumab (DEAR). A 7-Week, Placebo-Controlled, Double-Blinded, Parallel-Group, Imaging Study Using Positron Emission Tomography/Computer Tomography (PET/CT) to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation in Patients With Eosinophilic Asthma
Actual Study Start Date : May 8, 2017
Actual Primary Completion Date : May 24, 2017
Actual Study Completion Date : May 24, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
Drug Information available for: Reslizumab

Arm Intervention/treatment
Experimental: Part 1: PET/CT Scan
Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants will receive Fluorodeoxyglucose F-18 (FDG) as part of the PET/CT procedures and will provide sputum/blood samples.
Drug: Fludeoxyglucose F 18 (FDG)
FDG will be administered by IV infusion prior to each PET/CT scan.

Experimental: Part 2: Reslizumab
Reslizumab 3.0 milligrams/kilogram (mg/kg) will be administered by intravenous (IV) infusion, over 20 to 50 minutes, at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
Drug: Reslizumab
Reslizumab will be administered as per the dose and schedule specified in the arm.

Drug: Fludeoxyglucose F 18 (FDG)
FDG will be administered by IV infusion prior to each PET/CT scan.

Placebo Comparator: Part 2: Placebo
Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
Drug: Fludeoxyglucose F 18 (FDG)
FDG will be administered by IV infusion prior to each PET/CT scan.

Drug: Placebo
Placebo matching to reslizumab will be administered as per the schedule specified in the arm.




Primary Outcome Measures :
  1. Part 1: Average Global Lung Glycolysis (GLG) at Baseline (Day 1) [ Time Frame: Baseline (Day 1) of Part 1 ]
    GLG is the total FDG uptake in the whole lung. A region of interest (ROI) was drawn around lung boundary in each axial slice. Standardized uptake value (SUV) mean and area of each ROI was recorded. Using the formula: area*slice thickness the volume of each slice was calculated. Then the SUVmean of each slice was multiplied by the volume of the corresponding slice, which represented the total FDG uptake in one slice. This number for each slice was summed together to provide GLG of that lung. Average between GLG of right lung and GLG of left lung was reported.

  2. Part 1: Average Global Lung Glycolysis (GLG) at Day 8 [ Time Frame: Day 8 ]
    GLG is the total FDG uptake in the whole lung. ROI was drawn around lung boundary in each axial slice. SUV mean and area of each ROI was recorded. Using the formula: area*slice thickness the volume of each slice was calculated. Then the SUVmean of each slice was multiplied by the volume of the corresponding slice, which represented the total FDG uptake in one slice. This number for each slice was summed together to provide GLG of that lung. Average between GLG of right lung and GLG of left lung was reported.

  3. Part 2: Change From Baseline to Week 4 in GLG [ Time Frame: Baseline, Week 4 ]
  4. Part 2: Change From Baseline to Week 4 in Lung Parenchyma (LP) SUV Mean [ Time Frame: Baseline, Week 4 ]

Secondary Outcome Measures :
  1. Part 2: Change From Baseline to Week 4 in Blood Eosinophil Counts [ Time Frame: Baseline, Week 4 ]
  2. Change From Baseline to Week 4 in Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Baseline, Week 4 ]
  3. Change From Baseline to Week 4 in Fractional Exhaled Nitric Oxide (FeNO) [ Time Frame: Baseline, Week 4 ]
  4. Change From Baseline to Week 4 in Asthma Quality of Life Questionnaire (AQLQ) Score [ Time Frame: Baseline, Week 4 ]
  5. Number of Participants With Adverse Events (AEs) [ Time Frame: 21 days ]
    An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. SAEs included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female, 18 through 50 years of age.
  • Females that are either surgically sterile, are 2 years postmenopausal, or have a negative pregnancy test at screening.
  • Females of childbearing potential (not surgically sterile or 2 years postmenopausal), have to use a medically accepted method of contraception and have to agree to continue to use of this method for the duration of the study and for 5 months after study drug administration.
  • Participants with less that 10-pack year history of smoking.
  • Have a previous diagnosis of asthma.
  • Participants taking inhaled fluticasone at a dosage of at least 440 micrograms (mcg) daily, or equivalent.
  • The participant's baseline asthma therapy must be stable for 30 days prior to screening and judged by their treating physician to be able to continue without dosage changes throughout the study.
  • Participants with a blood eosinophil level of at least 400 cells/microliter (cells/μL) at screening. Participants with a blood eosinophil level below 400 cells/μL will be given 2 additional screening opportunities to determine blood eosinophil levels.

    • Additional criteria apply; please contact the investigator for more information.

Exclusion Criteria:

  • Participants requiring treatment with oral, intramuscular, or IV corticosteroids within 6 weeks of the Part 1 baseline visit for an asthma exacerbation.
  • Participants with any other confounding underlying lung disorder including but not limited to: bronchiectasis, chronic obstructive pulmonary disorder, smoking greater than or equal to (≥)10 pack year history, pulmonary fibrosis, emphysema, cystic fibrosis, and lung cancer.
  • Participants diagnosed with diabetes mellitus.
  • Participants with pulmonary conditions and blood eosinophilia other than eosinophilic asthma.
  • Participants with clinically meaningful comorbidity that can interfere with the study schedule or procedures, or compromise the participant's safety.
  • Participants that are current smokers (that is, have smoked within the last 12 months prior to screening).
  • Participants using systemic immunosuppressive, immunomodulating, or other biologic agents (including, but not limited to, anti-IgE mAb, methotrexate, cyclosporin, interferon-α, or anti-tumor necrosis factor mAb) within 6 months prior to screening. Participants whose treatment with anti-IgE mAb therapy (omalizumab) is considered ineffective by their physician may be included as potential participants when:

    1. The omalizumab (Xolair) therapy has been discontinued.
    2. The participant's blood eosinophil level meets inclusion criteria.
  • Participants who have previously received an anti-hIL-5 mAb (for example, reslizumab, mepolizumab [Nucala]) or anti-IL-5 receptor mAb (eg, benralizumab). Participants whose treatment with mepolizumab or benralizumab is considered ineffective by their physician may be included as potential participants when:

    1. The mepolizumab or benralizumab therapy has been discontinued.
    2. The participant's blood eosinophil level meets inclusion criteria.
  • Participants who had concurrent infection or disease that may preclude assessment of active asthma.
  • Participants with a history of concurrent immunodeficiency (human immunodeficiency virus or acquired immunodeficiency syndrome or congenital immunodeficiency).
  • Participants that had an active parasitic infection within 6 months prior to screening.
  • Participants with any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).
  • Known hypersensitivity to study drug or to FDG/contrast agents
  • Treatment with metformin.
  • Compromised renal function.

    • Additional criteria apply; please contact the investigator for more information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02937168


Locations
Layout table for location information
United States, New Jersey
Teva Investigational Site 13808
New Brunswick, New Jersey, United States, 08901
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
Investigators
Layout table for investigator information
Study Director: Teva Medical Expert, MD Teva Pharmaceuticals USA
  Study Documents (Full-Text)

Documents provided by Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. ):
Study Protocol  [PDF] June 24, 2016
Statistical Analysis Plan  [PDF] May 30, 2017


Layout table for additonal information
Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc.
ClinicalTrials.gov Identifier: NCT02937168    
Other Study ID Numbers: C38072-AS-40105
First Posted: October 18, 2016    Key Record Dates
Results First Posted: August 6, 2019
Last Update Posted: August 6, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Inflammation
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Pathologic Processes
Reslizumab
Fluorodeoxyglucose F18
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action
Anti-Asthmatic Agents
Respiratory System Agents